Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes

References

• Stevens GA, White RA, Flaxman SR, et al. Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990–2010. Ophthalmology 2013;120:2377-84
   PubMed Web of Science ®Google Scholar
• Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014;4:e004015
   PubMed Web of Science ®Google Scholar
• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-64
   PubMed Web of Science ®Google Scholar
• Ferris FL, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28:452-61
   PubMed Web of Science ®Google Scholar
• Narayan KMV, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care 2006;29:2114-16
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351-9
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203
   PubMed Web of Science ®Google Scholar
• Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and OCT thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol 2012;130:1153-61
   PubMedGoogle Scholar
• Dong N, Xu B, Wang BCL. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis 2013;19:1734-46
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011;118:626-35
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. SPC Iluvien 190 micrograms intravitreal implant in applicator. 2015. Available at: https://www.medicines.org.uk/emc/medicine/27636 [Last accessed October 20, 2016]
   Google Scholar
• Medicines and Healthcare products Regulatory Agency. Public Assessment Report. Mutual Recognition Procedure. Iluvien 190 micrograms Intravitreal Implant in Applicator (Fluocinolone acetonide). 2015. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf [Last accessed October 20, 2016]
   Google Scholar
• Datapharm. eMC Dictionary of Medicines and Devices browser. Available at: http://dmd.medicines.org.uk/DesktopDefault.aspx?tabid = 1 [Last accessed January 6, 2017]
   Google Scholar
• National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy. 2013. Available at: www.nice.org.uk/guidance/ta301 [Last accessed October 24, 2014]
   Google Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-7
   PubMed Web of Science ®Google Scholar
• Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin 2017;33(Suppl):5--17
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina 2010;30:1046-50
   PubMed Web of Science ®Google Scholar
• Haukoos JS, Newgard CD. Advanced statistics: missing data in clinical research – part 1: an introduction and conceptual framework. Acad Emerg Med 2007;14:662-8
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014;121:1892-903
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye 2017; (epub ahead of print)
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol 2016;16:3
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular oedema. Curr Med Res Opin 2017;33(Suppl):33--43
   PubMed Web of Science ®Google Scholar
• Wolf-Schnurrbusch UEK, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432-7
   PubMed Web of Science ®Google Scholar
• Zehetner C, Kirchmair R, Huber S, et al. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97:454-9
   PubMed Web of Science ®Google Scholar
• Carneiro ÂM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012;90:e25-30
   PubMed Web of Science ®Google Scholar
• Bakbak B, Ozturk BT, Gonul S, Gedik S. The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: a comparative study of two anti-VEGFs. Oman J Ophthalmol 2016;9:44-8
   PubMedGoogle Scholar
• Michalska-Małecka K, Kabiesz A, Kimsa MW, et al. Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration. Cin Interv 2016;11:357-65
   Google Scholar
• Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-705
   PubMed Web of Science ®Google Scholar
• Acharya NR, Sttitvarakul W, Qian Y, et al. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina 2011;31:1871-6
   PubMed Web of Science ®Google Scholar